OPEN APP
Home >Companies >News >Lupin gets USFDA nod for generic diabetes drug
Lupin gets USFDA nod for generic diabetes drug (Bloomberg)
Lupin gets USFDA nod for generic diabetes drug (Bloomberg)

Lupin gets USFDA nod for generic diabetes drug

Drug maker Lupin said it has received approval from the US health regulator to market a generic diabetes drug in America

UNITED STATES OF AMERICA : Drug maker Lupin on Tuesday said it has received approval from the US health regulator to market a generic diabetes drug in America.

The Mumbai-based company has received a tentative approval from the US Food and Drug Administration (USFDA) for its Empagliflozin tablets, in strengths of 10 mg and 25 mg, Lupin said in a statement.

The product is a generic version of Boehringer Ingelheim Pharmaceuticals, Inc's Jardiance tablets which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

As per IQVIA MAT March 2020 data, the drug had an annual sales of around USD 4,368 million in the US.

This story has been published from a wire agency feed without modifications to the text.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My Reads Redeem a Gift Card Logout